Abnormal screens among nonmutation carriers in the High Risk Ontario Breast Screening Program

Abstract

The Ontario Breast Screening Program was expanded in 2011 to offer annual MRI and mammography to women with high‐risk genetic mutations (e.g., BRCA1/2) and women with strong family histories and ≥25% estimated lifetime risk of breast cancer. Data to support high‐risk screening is less clear in the nonmutation carrier group, as MRI has lower specificity among this population. The potential unintended consequences may be considerable and need to be explored. We aimed to describe the frequency of abnormal screens and biopsies.